Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05005819 · ClinicalTrials.gov registry record · Phase 1
Evaluation of [18F]APN-1607 as a PET Biomarker
A Phase 1 study, sponsored by Invicro.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT05005819: Completed Phase 1 study, sponsored by Invicro.
NCT05005819 is a Phase 1 study that has completed, run by Invicro. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05005819, a Phase 1 study, has completed, sponsored by Invicro.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The overall goal of this protocol is to evaluate \[18F\]APN-1607 as a PET radiotracer for measuring longitudinal change in tau pathology in participants with PSP.
Primary Outcome
The within-group change in standardized uptake value ratios (SUVRs) of regional \[18F\]APN-1607 binding within a priori defined cortical and subcortical brain regions from Baseline to Week 36 and Week 72.
Interventions
- DRUG [18F] APN-1607
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-05-25 |
| Est. Completion | 2024-01-09 |
| Phase | Phase 1 |
What the finished NCT05005819 record still lists
NCT05005819 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which [18F] APN-1607 is the first listed.
NCT05005819 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05005819 about?
NCT05005819 is a clinical study titled "Evaluation of [18F]APN-1607 as a PET Biomarker". The overall goal of this protocol is to evaluate \[18F\]APN-1607 as a PET radiotracer for measuring longitudinal change in tau pathology in participants with PSP.
What is the current status of trial NCT05005819?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2021-05-25. Estimated completion is 2024-01-09.
What interventions are being tested in trial NCT05005819?
The interventions under investigation include: [18F] APN-1607 (DRUG).
Who is sponsoring clinical trial NCT05005819?
This trial is sponsored by Invicro, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05005819's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI